Randomized Controlled Trial
Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.
Psychopharmacology (Berl.). 2012 Feb 1; 219 (3): 715-25.
Randomized Controlled Trial
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Clin Ther. 2009 Jun 1;31 Pt 1:1405-23.